Lactobacillus fermentum V3 Strain for Inflammation and Cancer Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Lactobacillus strains are ineffective in inhibiting inflammation and colorectal cancer, as their bacterial cells cannot inhibit TNF-α secretion and are often inactivated by stomach acid before reaching the intestine, limiting their anti-inflammatory potential.
Innovation Solution
A novel Lactobacillus fermentum strain V3, isolated from dried bamboo shoots, which can exist in live or dead form and effectively inhibits TNF-α secretion and colorectal tumor growth, even when inactivated, offering a composition for treating or preventing inflammatory diseases and cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional Lactobacillus strains are administered to treat inflammation and colorectal cancer, then they are intended to provide anti-inflammatory effects, but they cannot inhibit TNF-α secretion and are inactivated by stomach acid before reaching the intestine
Solution Approach 1:
The patent changes the functional parameter of the Lactobacillus strain by selecting a specific strain (V3) that produces anti-inflammatory metabolites capable of inhibiting TNF-α secretion. This strain differs from conventional strains in its metabolic capabilities, allowing it to exert anti-inflammatory effects even when inactivated by stomach acid, thus resolving the contradiction between reliability and stomach acid sensitivity
Solution Approach 2:
The patent introduces metabolites as intermediary substances that mediate the anti-inflammatory effect. These metabolites are produced by the Lactobacillus V3 strain and can inhibit TNF-α secretion independently of bacterial viability, serving as intermediaries that transfer the anti-inflammatory function even when the bacteria themselves are inactivated by stomach acid
2Quantity of substance
If Lactobacillus bacteria are used to generate anti-inflammatory substances in the intestine, then they are intended to produce sufficient anti-inflammatory metabolites, but most bacteria are dead by the time they reach the intestine due to low tolerance to stomach acid and choline
Solution Approach 1:
The patent applies preliminary action by pre-producing and stabilizing anti-inflammatory metabolites within the Lactobacillus V3 strain before administration. The strain is engineered or selected to produce and maintain these metabolites in advance, so that even if the bacteria are inactivated by stomach acid, the pre-formed metabolites remain available to exert anti-inflammatory effects in the intestine
Solution Approach 2:
The patent converts the harmful effect of stomach acid inactivation into a benefit by demonstrating that the anti-inflammatory metabolites produced by Lactobacillus V3 remain stable and effective even when the bacteria themselves are killed. The harm of bacterial death is transformed into a benefit where the metabolites continue to function independently of bacterial viability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Lactobacillus fermentum strain V3 significantly reduces TNF-α production, suppresses intestinal inflammation, and decreases the number of colorectal tumors, demonstrating its effectiveness in preventing colorectal cancer and regulating intestinal microflora.
Implementation Method 1
The cell wall components of Gram-negative bacteria, Lipopolysaccharide (LPS), promotes the growth and spread of colorectal cancer cells by promoting the inflammatory response. Lactobacillus fermentum strain V3... effectively inhibits TNF-α secretion
Implementation Method 2
the changes in the intestinal microflora are significantly related to the formation of colorectal cancer... the number of Lactobacillus is negatively correlated with the incidence of colorectal cancer... Lactobacillus fermentum strain V3... regulating intestinal microflora
Data Source
AI summary
The present invention provides a novel Lactobacillus fermentum strain, named Lactobacillus fermentum strain V3, and its use in manufacturing a pharmaceutical composition or a food composition for regulating intestinal microflora and treating and/or preventing an inflammatory diseases and/or a cancer.